1
Clinical Trials associated with [11C]-NOP46Exploratory Evaluation of [11C]-NOP46 Pharmacokinetics With Positron Emission Tomography (PET)
This is an open-label, single center design. In the first stage, five (5) healthy individuals will receive a microdose (10µg) of [11C]-NOP46, immediately followed by whole body positron emission tomography (PET)/computed tomography (CT) to determine dosimetry and perform an initial safety evaluation of the radiotracer. If no toxicities develop, then the investigation will move to the second stage, in which thirty (30) patients with chronic pain will receive a microdose of [11C]-NOP46 followed by PET/CT of region of interests.
100 Clinical Results associated with [11C]-NOP46
100 Translational Medicine associated with [11C]-NOP46
100 Patents (Medical) associated with [11C]-NOP46
100 Deals associated with [11C]-NOP46